KR20240001759A - Composition for improving skin conditions comprising lactic acid bacteria fermentate of rice germ extract - Google Patents
Composition for improving skin conditions comprising lactic acid bacteria fermentate of rice germ extract Download PDFInfo
- Publication number
- KR20240001759A KR20240001759A KR1020220078104A KR20220078104A KR20240001759A KR 20240001759 A KR20240001759 A KR 20240001759A KR 1020220078104 A KR1020220078104 A KR 1020220078104A KR 20220078104 A KR20220078104 A KR 20220078104A KR 20240001759 A KR20240001759 A KR 20240001759A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- lactic acid
- acid bacteria
- extract
- fermented rice
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 112
- 235000007164 Oryza sativa Nutrition 0.000 title claims abstract description 74
- 235000009566 rice Nutrition 0.000 title claims abstract description 74
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 56
- 239000004310 lactic acid Substances 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 241000894006 Bacteria Species 0.000 title claims description 42
- 240000007594 Oryza sativa Species 0.000 title 1
- 210000003491 skin Anatomy 0.000 claims abstract description 124
- 241000209094 Oryza Species 0.000 claims abstract description 73
- 230000037303 wrinkles Effects 0.000 claims abstract description 40
- 235000013305 food Nutrition 0.000 claims abstract description 28
- 102000008186 Collagen Human genes 0.000 claims abstract description 26
- 108010035532 Collagen Proteins 0.000 claims abstract description 26
- 229920001436 collagen Polymers 0.000 claims abstract description 26
- 239000002537 cosmetic Substances 0.000 claims abstract description 24
- 230000037394 skin elasticity Effects 0.000 claims abstract description 21
- 102000004190 Enzymes Human genes 0.000 claims abstract description 19
- 108090000790 Enzymes Proteins 0.000 claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 17
- 210000002510 keratinocyte Anatomy 0.000 claims abstract description 17
- 102100028314 Filaggrin Human genes 0.000 claims abstract description 16
- 101710088660 Filaggrin Proteins 0.000 claims abstract description 16
- 230000007423 decrease Effects 0.000 claims abstract description 11
- 230000000638 stimulation Effects 0.000 claims abstract description 6
- 210000001161 mammalian embryo Anatomy 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 23
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 17
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 16
- 238000000855 fermentation Methods 0.000 claims description 15
- 230000004151 fermentation Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 5
- 235000013376 functional food Nutrition 0.000 claims description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 3
- 102000013142 Amylases Human genes 0.000 claims description 3
- 108010065511 Amylases Proteins 0.000 claims description 3
- 241000186612 Lactobacillus sakei Species 0.000 claims description 3
- 102000005158 Subtilisins Human genes 0.000 claims description 3
- 108010056079 Subtilisins Proteins 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 239000004382 Amylase Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 235000019418 amylase Nutrition 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims 1
- 239000012046 mixed solvent Substances 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 abstract description 9
- 230000006872 improvement Effects 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 15
- 239000006210 lotion Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 12
- 239000006071 cream Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 206010051246 Photodermatosis Diseases 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- -1 pack Substances 0.000 description 10
- 230000008845 photoaging Effects 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 230000003020 moisturizing effect Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000002500 effect on skin Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 101710108790 Stromelysin-1 Proteins 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 6
- 102100030416 Stromelysin-1 Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 238000009395 breeding Methods 0.000 description 6
- 230000001488 breeding effect Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 230000008591 skin barrier function Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 6
- 230000037373 wrinkle formation Effects 0.000 description 6
- 241000004045 Bouea oppositifolia Species 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 206010060891 General symptom Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000686 essence Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 108060008539 Transglutaminase Proteins 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000003601 transglutaminase Human genes 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 102100024308 Ceramide synthase Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 102100031784 Loricrin Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 108010061814 dihydroceramide desaturase Proteins 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 102000007236 involucrin Human genes 0.000 description 2
- 108010033564 involucrin Proteins 0.000 description 2
- 108010079309 loricrin Proteins 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 230000037067 skin hydration Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004958 Caspase-14 Human genes 0.000 description 1
- 108090001132 Caspase-14 Proteins 0.000 description 1
- 102100035435 Ceramide synthase 3 Human genes 0.000 description 1
- 101710146188 Ceramide synthase 3 Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 108700041153 Filaggrin Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000173371 Garcinia indica Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000001007 puffing effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000021127 solid diet Nutrition 0.000 description 1
- 238000010563 solid-state fermentation Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000003190 viscoelastic substance Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L35/00—Food or foodstuffs not provided for in groups A23L5/00 – A23L33/00; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/10—General methods of cooking foods, e.g. by roasting or frying
- A23L5/13—General methods of cooking foods, e.g. by roasting or frying using water or steam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/038—Gamma-amino butyric acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/28—Hydrolysis, degree of hydrolysis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/179—Sakei
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 유산균 발효 미배아 추출물을 포함하는 피부 상태 개선용 조성물에 관한 것으로, 보다 상세하게는 피부 주름 개선, 피부 탄력 개선 및 피부 보습 개선 효과를 나타내는 유산균 발효 미배아 추출물을 포함하는 식품 조성물, 약학적 조성물 및 화장료 조성물에 관한 것이다.
유산균 발효 미배아 추출물을 포함하는 본 발명의 조성물은 자외선 자극에 의한 피부 표피 두께 증가 억제, 피부 콜라겐 감소 억제, 콜라겐 분해효소 발현 억제 및 각질세포에서 필라그린(filaggrin)의 발현 증가 효과를 나타내어 피부 주름 개선, 피부 탄력 개선 및 피부 보습 증진용 제제 개발에 매우 유용하게 활용될 수 있다. The present invention relates to a composition for improving skin condition containing an extract of lactic acid bacteria-fermented rice germ, and more specifically, to a food composition containing an extract of lactic acid bacteria-fermented rice germ, which exhibits effects of improving skin wrinkles, improving skin elasticity, and improving skin moisturization, and pharmaceuticals. It relates to cosmetic compositions and cosmetic compositions.
The composition of the present invention containing lactic acid bacteria-fermented rice germ extract inhibits the increase in skin epidermal thickness caused by ultraviolet ray stimulation, inhibits the decrease in skin collagen, inhibits the expression of collagen decomposition enzymes, and increases the expression of filaggrin in keratinocytes, thereby causing skin wrinkles. It can be very useful in developing agents for skin improvement, skin elasticity, and skin moisturization.
Description
본 발명은 유산균 발효 미배아 추출물을 포함하는 피부 상태 개선용 조성물에 관한 것으로, 보다 상세하게는 피부 주름 개선, 피부 탄력 개선 및 피부 보습 개선 효과를 나타내는 유산균 발효 미배아 추출물을 포함하는 식품 조성물, 약학적 조성물 및 화장료 조성물에 관한 것이다. The present invention relates to a composition for improving skin condition containing an extract of lactic acid bacteria-fermented rice germ, and more specifically, to a food composition containing an extract of lactic acid bacteria-fermented rice germ, which exhibits effects of improving skin wrinkles, improving skin elasticity, and improving skin moisturization, and pharmaceuticals. It relates to cosmetic compositions and cosmetic compositions.
최근 의료기술의 발달로 평균수명이 연장되고 삶의 질 향상과 건강하고 아름다운 삶에 대한 욕구가 증가함에 따라 피부미용 및 건강에 대한 관심이 확대되고 있다. 이에 건강한 피부를 유지하고자 하는 목적에 따라 다양한 미용 기능성 화장품이 개발되었으며, 특히 피부 주름형성 예방, 완화와 개선을 위한 연구가 활발히 진행되고 있다. 아울러 최근 화장품의 성분이 피부진피에 도달하여 영양분을 공급하는데 한계가 있고, 식품으로 섭취하여 피부에 영양분 또는 기능성분을 공급하여 피부미용증진 효과를 나타낼 수 있다는 인식의 변화가 일어남에 따라 이너뷰티 식품소재들을 발굴하는 연구 또한 활발히 진행되고 있다.Recently, as the average lifespan has been extended due to the development of medical technology, the quality of life has improved, and the desire for a healthy and beautiful life has increased, interest in skin care and health is expanding. Accordingly, various beauty functional cosmetics have been developed for the purpose of maintaining healthy skin, and in particular, research on preventing, alleviating, and improving the formation of skin wrinkles is actively underway. In addition, there are recent limitations in the ability of cosmetic ingredients to reach the skin dermis and provide nutrients, and as there is a change in perception that ingestion of food can provide nutrients or functional ingredients to the skin to improve skin beauty, inner beauty foods Research to discover materials is also actively underway.
피부는 외부환경의 자극으로부터 체내의 기관들을 보호해주며, 체온조절 등의 생체 항상성 유지에 중요한 역할을 한다. 이러한 피부는 노화가 진행됨에 따라 피부 탄력 감소, 피부색 변화, 피부주름 형성 등의 외형적인 변형이 함께 수반된다. 이러한 피부 노화 과정은 나이가 들어감에 따라 자연히 발생하는 내인성 노화(intrinsic aging 또는 자연노화)와 외인성 노화인 주위 환경, 특히 자외선(ultraviolet; UV)에 의환 광노화(photoaging)가 복합적으로 작용해 나타난다. 두 가지 노화 사이에는 주름이 생성되는 기전이 세부적으로 차이가 있지만 피부에서는 표피 세포의 증식이나 신진대사가 저하되며, 표피-진피 사이의 결합이 약해 조그만 자극에도 손상을 입기 쉽고, 콜라겐 합성 감소와 과다한 콜라겐 분해 효소인 MMPs(Matrix Metalloproteinases)의 발현 증가 등의 생리적 변화들이 나타나 피부가 건조해지며 표피, 진피 층의 구조적 변화로 인해 피부가 탄력성을 잃고 늘어져 보이며 점차적으로 주름이 깊어지게 된다. 피부 노화 현상에서 자연노화 현상을 지연시키고 환경적이 요인인 자외선에 의한 광노화를 효과적으로 차단하는 것이 피부노화를 지연하고 억제하는 방법이다.The skin protects the internal organs from stimulation from the external environment and plays an important role in maintaining biological homeostasis, such as temperature regulation. As this type of skin ages, it is accompanied by external deformations such as decreased skin elasticity, changes in skin color, and formation of skin wrinkles. This skin aging process is caused by a combination of intrinsic aging, which occurs naturally as we age, and extrinsic aging, photoaging caused by the surrounding environment, especially ultraviolet rays (UV). There are detailed differences in the mechanisms by which wrinkles are formed between the two types of aging, but in the skin, the proliferation and metabolism of epidermal cells are reduced, the bond between the epidermis and dermis is weak, so it is easy to be damaged even by small stimuli, and collagen synthesis is reduced and excessive wrinkles occur. Physiological changes such as increased expression of collagen-decomposing enzyme MMPs (Matrix Metalloproteinases) occur, causing the skin to become dry, and due to structural changes in the epidermal and dermal layers, the skin loses elasticity and appears saggy, and wrinkles gradually deepen. The way to delay and suppress skin aging is to delay natural aging and effectively block photoaging caused by ultraviolet rays, which are environmental factors.
최근 환경오염으로 인한 오존층 파괴는 자외선의 양을 증가시켰고 이에 따라 광노화에 대한 연구가 주목되고 있다(Dermatology and Therapy, 23(1): 31-47, 2010). 광노화된 피부에서는 거칠어짐, 탄력 손실, 주름발생 등과 같은 외관상의 특징이 관찰되며, 이 중 광노화의 주된 연구 분야는 피부 주름의 변화에 대한 것이다. 상기 광노화에 의한 피부 주름형성에 관해 피부의 주요 구성성분인 콜라겐(collagen)의 합성, 분해 및 수분 함유량 등의 기초적인 생리 대사 변화에 대한 연구 결과가 다수 보고되고 있다(Annals of the New York Academy of Sciences, 973: 31-43, 2002).Recently, the destruction of the ozone layer due to environmental pollution has increased the amount of ultraviolet rays, and as a result, research on photoaging is attracting attention (Dermatology and Therapy, 23(1): 31-47, 2010). Appearance characteristics such as roughening, loss of elasticity, and wrinkles are observed in photoaged skin, and the main research field of photoaging is about changes in skin wrinkles. Regarding the formation of skin wrinkles due to photoaging, many research results have been reported on changes in basic physiological metabolism such as synthesis, decomposition, and moisture content of collagen, a major component of the skin (Annals of the New York Academy of Sciences, 973: 31-43, 2002).
피부 진피층에 존재하는 콜라겐은 피부 전체 건조 중량의 약 70-80%를 차지하며 탄력섬유인 엘라스틴(elastin)과 함께 피부의 탄력을 주관하는 것으로 알려져 있다. 특히 자외선에 의해 활성 산소종(reactive oxygen species) 생성이 증가되고 피부의 효소적, 비효소적 항산화 방어체계가 붕괴되어 콜라겐의 분해 증가 및 생합성을 감소시켜 진피층 내의 콜라겐이 현저하게 감소된다(Journal of Investigative Dermatology, 126(12): 2565-2575, 2006). 상기 콜라겐 감소에 중요한 영향을 미치는 것은 matrix metalloproteinases (MMP)로, 이는 세포외기질(extracellular matrix)과 기저막(basement membrane)의 분해에 관여한다. 상기 효소는 자외선에 의해 활성이 증가되며 이를 억제함으로써 자외선에 의해 유도되는 피부 두께 증가 및 주름 형성이 감소된다는 연구 결과들이 보고되어 있다(Journal of Investigative Dermatology, 120(1): 128-134, 2003). 따라서, 광노화의 예방 및 치료를 위해서는 MMP를 조절하는 것이 효과적인 방법이다.Collagen present in the dermal layer of the skin accounts for approximately 70-80% of the total dry weight of the skin and is known to control the elasticity of the skin along with elastin, an elastic fiber. In particular, ultraviolet rays increase the production of reactive oxygen species and the skin's enzymatic and non-enzymatic antioxidant defense system collapses, increasing collagen decomposition and reducing biosynthesis, resulting in a significant decrease in collagen in the dermal layer (Journal of Investigative Dermatology, 126(12): 2565-2575, 2006). Matrix metalloproteinases (MMPs) have an important effect on the collagen reduction, which is involved in the decomposition of the extracellular matrix and basement membrane. Research results have reported that the activity of the enzyme is increased by ultraviolet rays, and that by inhibiting it, the increase in skin thickness and wrinkle formation induced by ultraviolet rays are reduced (Journal of Investigative Dermatology, 120(1): 128-134, 2003) . Therefore, controlling MMP is an effective method for preventing and treating photoaging.
피부 각질층(stratum corneum)은 피부에서 최외각 층에 존재하고, 외부환경에 직접 접하고 있어 외부의 물리적 화학적 스트레스로부터 우리 몸을 보호하는 데 중요한 장벽기능(barrier function)을 담당하고 있다. 이러한 장벽기능은 표피의 항상성(homeostasis)에 의하여 유지된다. 표피 항상성은 기저층의 각질형성세포(keratinocytes)의 성장분열과 세포이동에 따른 분화 과정을 통해 최종 분화(terminal differentiation)를 거쳐 각질층으로 불리는 피부장벽을 형성함으로써 지속적인 피부 장벽 기능을 유지하는 것이다(Korean Journal of Food Science and Technology, 43: 458-463, 2011).The stratum corneum exists in the outermost layer of the skin and is in direct contact with the external environment, so it plays an important barrier function in protecting our bodies from external physical and chemical stresses. This barrier function is maintained by epidermal homeostasis. Epidermal homeostasis maintains continuous skin barrier function by forming a skin barrier called the stratum corneum through terminal differentiation through growth division and cell migration of keratinocytes in the basal layer (Korean Journal) of Food Science and Technology, 43: 458-463, 2011).
각질형성 세포가 분화함에 따라서 보습에 영향을 미치는 두 가지 요인을 생성한다. 첫째로, 각질형성세포가 분화하는 동안 그 세포막은 각질세포막(cornified envelope)이라는 구조물로 대체된다. 각질세포막은 loricrin (LOR), involucrin (INV), filaggrin (FLG)을 비롯한 여러 구조 단백질들이 transglutaminases (TGM)라는 효소에 의해 가교를 형성한 막 구조물로서 외부환경에 대한 피부 보호기능을 제공함과 동시에 각질세포내의 수분증발을 억제한다. 각질 세포막 구조 단백질과 TGM은 각질형성세포의 분화에 따라 발현되기 시작하므로 분화인자(differentiation marker)로서 사용된다(Nature Reviews Molecular Cell Biology, 6(4): 328-340, 2005). 따라서 각질 세포막과 분화인자는 보습의 지표로써 사용된다. 또한, 각질세포의 분화 과정 중에 각질형성세포는 천연보습인자(natural moisturizing factor; NMF)를 생성하면서 피부장벽(skin barrier)으로서의 기능을 보유하게 한다. 천연보습인자들의 생성에 중요한 원천이 되는 단백질은 FLG로서, FLG은 카스파아제 14(caspase 14)에 의해 친수성 아미노산으로 분해되어 천연보습인자을 형성한다. 천연보습인자는 수분 보유 능력(water holding capacity)과 대기 중의 수분 흡습력(moisture absorption)을 제공함으로써 피부 내 보습력을 유지하는 기능을 한다(Journal of Cell Science, 122: 1285-1294, 2009). 따라서 피부에 적절한 수준의 천연보습인자를 유지하는 것은 피부 장벽 기능을 통한 피부 건강에 매우 중요한 요소이다. 둘째로, 피부 각질층을 구성하는 각질세포간 지질은 세라마이드(ceramide), 콜레스테롤, 유리지방산 등의 지질성분으로 구성되어있다. 스핑고지질(sphingolipid)의 일종인 세라마이드는 각질세포간 지질 중 약 40% 이상을 차지하기 때문에, 피부장벽 기능하는 각질층의 구조를 형성하는 필수적인 성분이다. 세라마이드 합성효소(ceramide synthase; CerS)가 세라마이드 합성에 가장 중요한 효소로, 각질층에 존재하는 세라마이드의 대부분은 CerS3에 의해 합성된다(Biochimie, 91; 784-790, 2009; Biochimica et Biophysica Acta, 1841; 422-434, 2014).As keratinocytes differentiate, they produce two factors that affect moisturization. First, during keratinocyte differentiation, the cell membrane is replaced by a structure called the cornified envelope. The keratinocyte membrane is a membrane structure in which several structural proteins, including loricrin (LOR), involucrin (INV), and filaggrin (FLG), are cross-linked by enzymes called transglutaminases (TGM). It provides skin protection against the external environment and at the same time protects the skin from keratin. Inhibits moisture evaporation within cells. Keratinocyte membrane structural proteins and TGM begin to be expressed upon differentiation of keratinocytes and are therefore used as differentiation markers (Nature Reviews Molecular Cell Biology, 6(4): 328-340, 2005). Therefore, keratin cell membrane and differentiation factors are used as indicators of moisturization. Additionally, during the differentiation process of keratinocytes, keratinocytes produce natural moisturizing factor (NMF) and retain the function of a skin barrier. The protein that is an important source for the production of natural moisturizing factors is FLG. FLG is decomposed into hydrophilic amino acids by caspase 14 to form natural moisturizing factors. Natural moisturizing factors function to maintain moisturizing power in the skin by providing water holding capacity and moisture absorption from the atmosphere (Journal of Cell Science, 122: 1285-1294, 2009). Therefore, maintaining an appropriate level of natural moisturizing factors in the skin is a very important factor for skin health through skin barrier function. Second, the interkeratinocyte lipids that make up the stratum corneum of the skin are composed of lipid components such as ceramide, cholesterol, and free fatty acids. Ceramide, a type of sphingolipid, accounts for more than 40% of lipids between keratinocytes and is an essential component that forms the structure of the stratum corneum that functions as a skin barrier. Ceramide synthase (CerS) is the most important enzyme in ceramide synthesis, and most of the ceramide present in the stratum corneum is synthesized by CerS3 (Biochimie, 91; 784-790, 2009; Biochimica et Biophysica Acta, 1841; 422 -434, 2014).
이에, 본 발명자는 천연물 유래의 피부 주름, 탄력 저하 및 피부 내 수분 저하 예방, 개선 또는 치료 효과가 있는 물질을 개발하기 위해 연구를 거듭한 결과, 가바(γ-aminobutyric acid, GABA)를 고함량으로 포함하는 유산균 발효 미배아 추출물이 피부 상태 개선에 매우 우수한 효과를 나타낸다는 것을 발견하고 본 발명을 완성하게 되었다. Accordingly, the present inventor has conducted repeated research to develop a substance derived from natural products that has the effect of preventing, improving, or treating skin wrinkles, loss of elasticity, and loss of moisture in the skin, and as a result, high content of γ-aminobutyric acid (GABA) was used. The present invention was completed after discovering that a lactic acid bacteria-fermented rice germ extract exhibits a very excellent effect in improving skin condition.
따라서, 본 발명의 목적은 유산균 발효 미배아 추출물을 유효성분으로 포함하는 피부 탄력 또는 주름 개선용 식품, 약학적 또는 화장료 조성물을 제공하는 것이다. Therefore, the purpose of the present invention is to provide a food, pharmaceutical or cosmetic composition for improving skin elasticity or wrinkles containing lactic acid bacteria fermented rice embryo extract as an active ingredient.
본 발명의 다른 목적은 유산균 발효 미배아 추출물을 유효성분으로 포함하는 피부 보습 증진용 식품, 약학적 또는 화장료 조성물을 제공하는 것이다. Another object of the present invention is to provide a food, pharmaceutical or cosmetic composition for improving skin moisturization containing lactic acid bacteria fermented rice germ extract as an active ingredient.
전술한 본 발명의 목적을 달성하기 위하여, 본 발명은 유산균 발효 미배아 추출물을 유효성분으로 포함하는 피부 탄력 또는 주름 개선용 식품, 약학적 또는 화장료 조성물을 제공한다.In order to achieve the above-described object of the present invention, the present invention provides a food, pharmaceutical or cosmetic composition for improving skin elasticity or wrinkles containing lactic acid bacteria fermented rice embryo extract as an active ingredient.
본 발명의 다른 목적을 달성하기 위하여, 본 발명은 유산균 발효 미배아 추출물을 유효성분으로 포함하는 피부 보습 증진용 식품, 약학적 또는 화장료 조성물을 제공한다. In order to achieve another object of the present invention, the present invention provides a food, pharmaceutical or cosmetic composition for improving skin moisturization containing lactic acid bacteria fermented rice germ extract as an active ingredient.
이하, 본 발명에 대해 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 명세서 전체에 걸쳐, 특정 물질의 농도를 나타내기 위하여 사용되는 '%'는 별도의 언급이 없는 경우, 고체/고체는 (w/w) %, 고체/액체는 (w/v) %, 그리고 액체/액체는 (v/v) %이다.Throughout this specification, '%' used to indicate the concentration of a specific substance means (w/w) % for solid/solid, (w/v) % for solid/liquid, and Liquid/liquid is (v/v) %.
본 발명의 용어, “미배아 추출물”은 배아 선별시스템을 갖춘 가공공장에서 생산된 청결 미배아를 물 등의 용매로 추출 처리하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액을 포함한다.The term “unripe embryo extract” in the present invention includes an extract obtained by extracting and processing clean rice embryos produced in a processing plant equipped with an embryo selection system with a solvent such as water, and a dilution or concentrate of the extract.
상기 미배아를 추출하는 방법은 특별히 제한되지 않으며, 당해 기술분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출 방법의 비 제한적인 예로는, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2종 이상의 방법을 병용하여 수행될 수 있다.The method for extracting the embryo is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include hot water extraction, ultrasonic extraction, filtration, and reflux extraction, which may be performed alone or by combining two or more methods.
본 발명의 상기 미배아 추출물은, 추출물 제조시 미배아를 안정화시키고 추출 효율을 증대시키기 위해 상기 미배아를 분쇄, 배전, 성형, 압출, 팽화, 과열수증기 처리 등 전처리 한 후 추출한 것일 수 있다.The uncooked embryo extract of the present invention may be extracted after pre-treating the uncooked embryos, such as grinding, roasting, molding, extrusion, puffing, and superheated steam treatment, in order to stabilize the unborn embryos and increase extraction efficiency during extract production.
일 구현예에서 배아를 물에 침지 또는 물을 분무하여 하여 수분함량 10~20%로 습윤 시킨 후 유동층 장치에서 170~350℃ 과열수증기 (superheated steam)로 5~60초간 처리하여 수열 팽화(hydrothermal expansion) 처리하였다.In one embodiment, the embryos are wetted to a moisture content of 10-20% by immersing or spraying water in water, and then treated with superheated steam at 170-350°C for 5-60 seconds in a fluidized bed device to achieve hydrothermal expansion. ) was processed.
본 발명의 상기 미배아 추출물은, 추출물 제조시 추출 효율을 증대시키고 다양한 가수분해 산물을 생성시키기 위해 상기 전처리한 미배아를 단백질 가수분해 효소, 섬유소 가수분해 효소, 지방 가수분해 효소 등의 한 개 이상의 효소로 가수분해한 후 추출한 효소가수분해 된 미배아 추출물일 수 있다.The rice embryo extract of the present invention is prepared by mixing the pretreated rice embryo with one or more enzymes such as proteolytic enzymes, cellulolytic enzymes, and fat hydrolytic enzymes in order to increase extraction efficiency and produce various hydrolysis products during extract production. It may be an enzymatically hydrolyzed rice embryo extract extracted after hydrolysis with an enzyme.
일 구현예에서 배아를 40~80 메쉬로 분쇄한 후 10% 농도로 물에 현탁시키고 여기에 단백질 분해효소 알카레이스 (alcalase), 전분가수분해 효소 아밀레이스 (amylase), 섬유소 가수분해 효소 셀루크라스트 (celluclast)를 각각 미배아 중량의 0.5~1.5%를 첨가하고 50~70℃에서 12~24 시간 가수분해 시킨 후 추출하였다.In one embodiment, the embryo is ground to a 40-80 mesh and suspended in water at a concentration of 10%, and the proteolytic enzyme alcalase, the starch hydrolytic enzyme amylase, and the cellulolytic enzyme Cellucrast are added. (Celluclast) was added at an amount of 0.5 to 1.5% of the weight of each embryo, hydrolyzed at 50 to 70°C for 12 to 24 hours, and then extracted.
본 발명의 상기 미배아 추출물은, 추출물 제조 시 기능성 펩타이드 등 다양한 생리활성물질을 생성시키기 위해 상기 전처리한 미배아를 우수한 발효미생물인 바실러스 서브틸러스 TP-6(Bacillus subtilis TP-6)(KFCC 11343P)로 고체발효 또는 심부발효 한 후 추출한 발효된 미배아 추출물일 수 있다.The rice embryo extract of the present invention is prepared by mixing the pretreated rice embryo with Bacillus subtilis TP-6 (KFCC 11343P), an excellent fermentation microorganism, in order to produce various bioactive substances such as functional peptides during extract production. ) It may be a fermented rice germ extract extracted after solid-state fermentation or deep fermentation.
본 발명의 미배아 추출물은 물 및 탄소수 1 내지 8의 유기용매로 이루어지는 군에서 선택되는 하나 이상의 것을 사용하여 추출되는 것일 수 있다. 본 발명에서 추출 용매는 식용 가능한 단수 또는 복수 종류의 용매일 수 있으나, 바람직하게는 물, 주정, 및 탄소수 1 내지 6의 알코올[메탄올(C1), 에탄올(C2), 프로판올(C3), 부탄올(C4), 펜탄올(C5), 헥산올(C6)]로 이루어진 군에서 선택된 하나 이상의 것을 사용할 수 있다. 더 바람직하게는, 본 발명에서 상기 미배아 추출물은 물을 용매로 추출한 것일 수 있다. The rice embryo extract of the present invention may be extracted using one or more substances selected from the group consisting of water and organic solvents having 1 to 8 carbon atoms. In the present invention, the extraction solvent may be a single or plural type of edible solvent, but is preferably water, alcohol, and alcohol having 1 to 6 carbon atoms [methanol (C1), ethanol (C2), propanol (C3), butanol ( C4), pentanol (C5), and hexanol (C6)] can be used. More preferably, in the present invention, the uncooked embryo extract may be obtained by extracting water with a solvent.
본 발명의 미배아 추출물은 원심분리, 여과, 막분리 및 크로마토그래피 등 후처리 하여 유산균 배지로 사용할 수 있다. The rice embryo extract of the present invention can be used as a lactic acid bacteria medium after post-processing such as centrifugation, filtration, membrane separation, and chromatography.
본 발명에서 미배아 추출물에 유산균을 접종하고 발효시키기 전에 그 유산균의 생육과 목적하는 대사산물 생산을 촉진하기 위하여 미배아 추출물에 그 유산균의 탄소원, 질소원, 미네랄 등의 영양성분과 글루탐산 또는 글루탐산염을 첨가할 수 있다. 이러한 영양성분의 구체적이 종류와 그 첨가량 및 발효조건 등은 의도한 발효 시간, 발효 정도 등을 고려하여 당업계에 알려진 통상의 유산균 발효 범위 내에서 실험적으로 결정될 수 있다. In the present invention, before inoculating and fermenting lactic acid bacteria in the rice embryo extract, nutrients such as carbon source, nitrogen source, and minerals of the lactic acid bacteria and glutamic acid or glutamate are added to the rice embryo extract in order to promote the growth of the lactic acid bacteria and production of the desired metabolites. It can be added. The specific types of nutrients, their addition amounts, and fermentation conditions can be experimentally determined within the range of normal lactic acid bacteria fermentation known in the art, taking into account the intended fermentation time, degree of fermentation, etc.
본 발명에서 사용된 용어 “유산균 발효 미배아 추출물”이란 가바 생산능을 가진 유산균으로 상기 미배아 추출물을 발효시킨 것을 의미한다. 선택적으로, 발효 후 추가로 살균, 탈색, 여과 또는 원심분리, 농축, 이온교환 크로마로그래피, 결정화, 건조 등의 여러 단계의 후처리공정을 거처 얻은 농축액, 분말, 입상, 결정 등의 형태의 산물로 제형화한 것도 상기 유산균 발효 미배아 추출물의 범위에 포함된다. The term “lactic acid bacteria fermented rice embryo extract” used in the present invention means that the rice embryo extract is fermented with lactic acid bacteria having GABA production ability. Optionally, after fermentation, products in the form of concentrates, powders, granules, crystals, etc. are obtained through several post-treatment processes such as sterilization, decolorization, filtration or centrifugation, concentration, ion exchange chromatography, crystallization, and drying. Formulated with is also included in the scope of the lactic acid bacteria fermented rice embryo extract.
일 구현예에서, 상기 유산균 발효 미배아 추출물은 가바를 10 내지 20% (w/w) 함유한 분말일 수 있다. 본 발명의 일 실시예에서 발효조성물은 미배아 추출물을 발효원으로 기탁번호 KFCC11321인 락토바실러스 사케이(Lactobacillus sakei) B2-16를 접종, 발효하여 제조한 유산균 발효 미배아 추출물이며, 가바를 약 15% (w/w) 함유한다.In one embodiment, the lactic acid bacteria fermented rice germ extract may be a powder containing 10 to 20% (w/w) GABA. In one embodiment of the present invention, the fermented composition is a lactic acid bacteria-fermented rice embryo extract prepared by inoculating and fermenting the rice embryo extract with Lactobacillus sakei B2-16, accession number KFCC11321, as a fermentation source, and having a GABA of about 15. % (w/w).
일 구현예에서, 상기 유산균 발효 미배아 추출물은 정제, 탈염하여 가바가 20 내지 80% (w/w) 함유된 농축액일 수 있다.In one embodiment, the lactic acid bacteria-fermented rice embryo extract may be purified and desalted to form a concentrate containing 20 to 80% (w/w) GABA.
일 구현예에서, 상기 발효 미배아 추출물은 GABA를 5 내지 90% (w/w), 바람직하게는 10 내지 20%(w/w) 함유한 분말 또는 입상일 수 있다.In one embodiment, the fermented rice germ extract may be powder or granular containing 5 to 90% (w/w) GABA, preferably 10 to 20% (w/w).
일 구현예에서, 상기 유산균 발효 미배아 추출물은 정제, 탈염, 농축, 결정화 시킨 순도 90% 이상의 결정형태일 수 있다.In one embodiment, the lactic acid bacteria-fermented rice embryo extract may be in a crystal form with a purity of 90% or more after purification, desalting, concentration, and crystallization.
본 발명에서 상기 미배아(쌀눈)에는 단백질, 비타민, 미네랄 등 영양성분이 풍부하게 함유되어 있고, 옥타코사놀, 알파토코페롤, 감마오리자놀, 감마아미노부티르산, 식이섬유, 레시틴, 불포화지방산(리놀레산, 리노렌산, 올레산) 을 비롯하여 뛰어난 생리활성 물질이 다량 함유되어 있어 그 어떤 소재와도 비교할 수 없는 안전하고 완전한 식품소재 및 화장품 소재이다. In the present invention, the rice germ (rice germ) is rich in nutrients such as proteins, vitamins, and minerals, and contains octacosanol, alpha-tocopherol, gamma oryzanol, gamma aminobutyric acid, dietary fiber, lecithin, and unsaturated fatty acids (linoleic acid, linolenic acid, It contains a large amount of excellent biologically active substances, including oleic acid, and is a safe and complete food and cosmetic material that cannot be compared to any other material.
더욱이 이와 같은 미배아를 발효원으로 하여 다양한 효소가수분해, 고초균 및 유산균 발효기법을 적용하게 되면, 미배아 유래의 각종 영양소와 생리활성 물질을 비롯하여 발효과정 중에 생성되는 기능성 펩타이드, 가바 등 유용한 미생물 대사산물이 생성되게 될 것이므로 피부 주름, 탄력 저하 및 피부 내 수분 저하 예방, 개선 또는 치료 효과 등을 동시에 기대할 수 있는 융합 컨셉의 발효물을 개발할 수 있을 것이다. Moreover, when various enzymatic hydrolysis, Bacillus subtilis, and lactic acid bacteria fermentation techniques are applied using the rice embryo as a fermentation source, various nutrients and bioactive substances derived from the rice embryo, as well as functional peptides and GABA produced during the fermentation process, are metabolized by useful microorganisms. Since the product will be produced, it will be possible to develop a fermentation product with a fusion concept that can simultaneously expect the effects of preventing, improving, or treating skin wrinkles, loss of elasticity, and loss of moisture in the skin.
본 발명의 일 실시예에 따르면, 상기 유산균 발효 미배아 추출물은 자외선 자극에 의한 피부 표피 두께 증가 억제, 피부 콜라겐 감소 억제, 콜라겐 분해효소 발현 억제 및 각질세포에서 필라그린(filaggrin)의 발현 증가 효과를 나타내어 피부 주름 개선, 피부 탄력 개선 및 피부 보습 개선 효과가 매우 우수한 것으로 확인되었다. According to one embodiment of the present invention, the lactic acid bacteria fermented rice germ extract has the effect of inhibiting the increase in skin epidermal thickness due to ultraviolet ray stimulation, inhibiting the decrease of skin collagen, inhibiting the expression of collagen decomposition enzyme, and increasing the expression of filaggrin in keratinocytes. It was confirmed to be very effective in improving skin wrinkles, skin elasticity, and skin moisturization.
본 발명에 있어서, "피부 주름 개선"은 피부의 주름 및 탄력과 관련된 능력을 유지 또는 강화시키는 것을 의미한다. 피부 진피층의 교원섬유인 콜라겐(collagen)과 탄력섬유인 엘라스틴(elastin)이 그러한 역할을 하는 주요 단백질로서 피부 탄력을 주관하는데, 콜라겐의 생합성은 피부의 내, 외적 영향을 받게 된다. 구체적으로, 피부세포는 자연 노화로 인하여 세포 활성이 감소되면 콜라겐 섬유의 감소가 일어나거나, 또는 외적 요인으로서 자외선의 과량 조사되거나 스트레스 등에 의해 생성된 활성 산소가 단백질의 티올기(thiol: -SH)와 반응하여 효소 활성을 저해하거나, 콜라겐, 엘라스틴 등의 분해 효소의 발현을 증가시켜 피부의 주름을 증가시키고 탄력을 감소시켜 피부 노화가 진행된다.In the present invention, “skin wrinkle improvement” means maintaining or strengthening the skin's ability to wrinkle and elasticity. Collagen, a collagen fiber in the dermal layer of the skin, and elastin, an elastic fiber, are the main proteins that play such roles and control skin elasticity, and the biosynthesis of collagen is affected by the internal and external influences of the skin. Specifically, in skin cells, when cell activity decreases due to natural aging, collagen fibers decrease, or active oxygen generated by excessive irradiation of ultraviolet rays or stress as an external factor destroys the thiol group (thiol: -SH) of the protein. It reacts with and inhibits enzyme activity or increases the expression of enzymes that decompose collagen, elastin, etc., increasing skin wrinkles and reducing elasticity, leading to skin aging.
본 발명에 있어서, “피부 탄력 개선”이라 함은 피부에 대한 탄력성이 증가되는 것으로, 콜라겐 분해효소를 억제하고 콜라겐 생성을 촉진하여 피부 탄력의 손실을 억제 또는 저해하거나, 이미 감소된 탄력을 완화시키는 것을 말한다.In the present invention, “improvement of skin elasticity” refers to an increase in the elasticity of the skin, which inhibits collagen decomposition enzymes and promotes collagen production to suppress or inhibit the loss of skin elasticity or alleviate already reduced elasticity. says that
본 발명에 있어서, “피부 보습 증진”이라 함은 각질형성 세포의 분화를 촉진하여 피부의 수분이 감소되는 것을 저해 또는 억제하거나 피부의 수분 함유량을 증가시켜 피부 표면을 매끄럽게 하며, 윤기를 부여하는 것을 말한다. 또한, 각질세포에서 포함된 보습성분 단백질인 필라그린(Filaggrin)의 발현이 증가되는 것을 의미할 수 있다. In the present invention, “promoting skin moisturization” refers to promoting the differentiation of keratinocytes to inhibit or suppress the decrease in skin moisture or to increase the moisture content of the skin to smooth the skin surface and provide gloss. says Additionally, it may mean that the expression of Filaggrin, a moisturizing protein contained in keratinocytes, is increased.
본 명세서 내 "피부 광노화"는 일광노출(자외선)에 의해 피부가 노화되는 생리현상을 의미하는 것으로서, 장기간 동안 태양(자외선)에 노출되면, 얼굴, 목에 깊은 주름을 증가시키고 또 피부의 건조 및 피부 표면이 거칠어지거나 반점, 주근깨 등의 색소침착을 일으킨다.“Skin photoaging” in this specification refers to a physiological phenomenon in which the skin ages due to exposure to sunlight (ultraviolet rays). When exposed to the sun (ultraviolet rays) for a long period of time, deep wrinkles increase on the face and neck, and drying and drying of the skin occurs. It causes the skin surface to become rough or pigmentation such as spots and freckles.
본 발명의 식품 조성물은 건강 기능성 식품(functional food), 영양보조제(nutritional supplement), 건강식품(health food) 및 식품 첨가제(food additives) 등의 모든 형태를 포함한다.The food composition of the present invention includes all types of functional foods, nutritional supplements, health foods, and food additives.
상기 유형의 식품 조성물은 당업계에 공지된 통상적인 방법에 따라 다양한 형태로 제조할 수 있다. 이에 한정되지 않지만 예를 들면, 건강식품으로는 고사리 추출물의 유산균 발효물을 차, 쥬스 및 드링크의 형태로 제조하여 음용할 수 있도록 액상화, 과립화, 캡슐화 및 분말화하여 섭취할 수 있다. 또한, 상기 유산균 발효 미배아 추출물과 함께 피부 상태 개선에 효과가 있다고 알려진 공지의 활성 성분과 함께 혼합하여 조성물의 형태로 제조할 수 있다. 또한, 기능성 식품으로는 이에 한정되지 않지만 음료(알콜성 음료 포함), 과실 및 그의 가공식품(예: 과일통조림, 병조림, 잼, 마말레이드 등), 어류, 육류 및 그 가공식품(예: 햄, 소시지 콘비이프 등), 빵류 및 면류(예: 우동, 메밀국수, 라면, 스파게티, 마카로니 등), 과즙, 각종 드링크, 쿠키, 엿, 유제품(예: 버터, 치즈 등), 식용식물유지, 마아가린, 식물성 단백질, 레토르트 식품, 냉동식품, 각종 조미료(예: 된장, 간장, 소스 등) 등에 유산균 발효 미배아 추출물을 첨가하여 제조할 수 있다. 또한, 유산균 발효 미배아 추출물을 첨가제의 형태로 사용하기 위해서는 분말 또는 농축액 형태로 제조하여 사용할 수 있다.Food compositions of this type can be prepared in various forms according to conventional methods known in the art. Although not limited to this, for example, as a health food, the fermented lactic acid bacteria of fern extract can be prepared in the form of tea, juice, and drinks and consumed by liquefying, granulating, encapsulating, and powdering them for drinking. In addition, it can be prepared in the form of a composition by mixing the lactic acid bacteria fermented rice germ extract with known active ingredients known to be effective in improving skin condition. In addition, functional foods include, but are not limited to, beverages (including alcoholic beverages), fruits and their processed foods (e.g. canned fruit, bottled foods, jam, marmalades, etc.), fish, meat and their processed foods (e.g. ham, sausages, etc.) corned beef, etc.), bread and noodles (e.g. udon, buckwheat noodles, ramen, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, taffy, dairy products (e.g. butter, cheese, etc.), edible vegetable oil, margarine, vegetable oil It can be manufactured by adding lactic acid fermented rice germ extract to proteins, retort foods, frozen foods, and various seasonings (e.g., soybean paste, soy sauce, sauce, etc.). Additionally, in order to use the lactic acid bacteria fermented rice germ extract in the form of an additive, it can be prepared and used in the form of powder or concentrate.
본 발명의 식품 조성물 중 유산균 발효 미배아 추출물의 바람직한 함유량으로는 이에 한정되지 않지만 바람직하게는 최종적으로 제조된 식품 중 0.1 내지 90 중량%이다. 더 바람직하게는, 본 발명의 유산균 발효 미배아 추출물을 유효성분으로 함유하는 식품 조성물은 특히, 피부 상태 개선 효과가 있는 것으로 알려진 활성 성분과 함께 혼합하여 건강기능식품 또는 식이 보충제의 형태로 제조될 수 있다.The preferred content of the lactic acid bacteria fermented rice germ extract in the food composition of the present invention is not limited thereto, but is preferably 0.1 to 90% by weight of the final manufactured food. More preferably, the food composition containing the lactic acid bacteria fermented rice germ extract of the present invention as an active ingredient can be prepared in the form of a health functional food or dietary supplement by mixing it with an active ingredient known to have an effect of improving skin condition. there is.
본 발명의 화장료 조성물은 일반적인 유화 제형 및 가용화 제형의 형태일 수 있다. 예컨대, 유연 화장수 또는 영양 화장수 등과 같은 화장수, 훼이셜 로션, 바디로션 등과 같은 유액, 영양 크림, 수분 크림, 아이 크림 등과 같은 크림, 에센스, 화장연고, 스프레이, 젤, 팩, 선 스크린, 메이크업 베이스, 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션, 파우더, 클렌징 크림, 클렌징 로션, 클렌징 오일과 같은 메이크업 제거제, 클렌징 폼, 비누, 바디 워쉬 등과 같은 세정제 등의 제형을 가질 수 있다. 상기 화장료 조성물은 제형에 따라서 통상적으로 사용되는 성분을 더 포함할 수 있다.The cosmetic composition of the present invention may be in the form of a general emulsified formulation or solubilized formulation. For example, lotion such as flexible lotion or nourishing lotion, emulsion such as facial lotion, body lotion, cream, essence, cosmetic ointment, spray, gel, pack, sunscreen, makeup base, liquid such as nutritional cream, moisture cream, eye cream, etc. It may have a formulation such as foundation type, solid type or spray type, powder, makeup remover such as cleansing cream, cleansing lotion, cleansing oil, cleansing foam, soap, body wash, etc. The cosmetic composition may further include commonly used ingredients depending on the formulation.
또한, 상기 화장료 조성물은 유산균 발효 미배아 추출물에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다.In addition, the cosmetic composition contains, in addition to the lactic acid bacteria fermented rice germ extract, fatty substances, organic solvents, solubilizers, thickening agents and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, Commonly used in water, ionic or non-ionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or in cosmetics. It may contain auxiliaries commonly used in the field of cosmetology, such as any other ingredients.
상기 화장료 조성물은 유효성분이 단기간 내에 피부에 머무르게 되는 메이크업 제거제, 세정제 등과 같은 워쉬-오프(wash-off) 타입의 화장품의 경우에는 비교적 높은 농도의 상기 마리안 플럼 추출물을 포함할 수 있을 것이다. 반면, 유효성분이 장기간 동안 피부에 머무르게 되는 화장수, 유액, 크림, 에센스 등의 리브-온(leave-on) 타입의 화장품의 경우에는 워쉬-오프 타입의 화장품에 비해 낮은 농도의 상기 마리안 플럼 추출물을 포함해도 무방할 것이다. 이에 제한되는 것은 아니나, 본 발명의 한 구체예에서, 상기 조성물은 상기 마리안 플럼 추출물을 전체 조성물 중량에 대하여 0.001 중량% 내지 10 중량%(바람직하게는 0.01 중량% 내지 5 중량%)로 포함할 수 있다. 본 발명의 조성물이 상기 마리안 플럼 추출물을 0.001 중량% 미만으로 포함할 경우에는 충분한 피부 노화, 피부 주름, 탄력 저하 및 피부 내 수분 저하 예방 또는 개선 효과를 기대할 수 없고, 10 중량%를 초과하여 포함할 경우에는 알러지 등 원치 않는 반응이 발생하거나 피부 안전성에 문제가 있을 수 있으므로 이를 방지하기 위한 것이다.The cosmetic composition may contain a relatively high concentration of the Marian plum extract in the case of wash-off type cosmetics such as makeup removers and detergents in which the active ingredient stays on the skin for a short period of time. On the other hand, leave-on type cosmetics such as lotions, emulsions, creams, and essences, where the active ingredients stay on the skin for a long period of time, contain the Marian plum extract at a lower concentration than wash-off type cosmetics. It would be okay to do so. Although not limited thereto, in one embodiment of the present invention, the composition may include the Marian plum extract in an amount of 0.001% by weight to 10% by weight (preferably 0.01% by weight to 5% by weight) based on the total weight of the composition. there is. If the composition of the present invention contains the Marian plum extract in an amount of less than 0.001% by weight, a sufficient effect of preventing or improving skin aging, skin wrinkles, loss of elasticity and moisture loss in the skin cannot be expected, and if the composition of the present invention contains the Marian plum extract in an amount exceeding 10% by weight. This is to prevent unwanted reactions such as allergies or skin safety issues.
또한 본 발명의 화장료 조성물은 유산균 발효 미배아 추출물을 유효성분으로 포함하는 화장수류, 에센스류, 스킨류, 로션류, 크림류, 팩류로 이루어진 군으로부터 선택된 어느 하나의 제형을 갖는 화장품으로 제공될 수 있다.In addition, the cosmetic composition of the present invention can be provided as a cosmetic product having any one formulation selected from the group consisting of lotions, essences, skins, lotions, creams, and packs containing lactic acid bacteria fermented rice embryo extract as an active ingredient. .
상기 화장품은 일 예로 스킨, 스킨소프터, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림 모이스쳐크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비소, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클렌저 등이 있으나, 이에 한정되는 것은 아니다.Examples of the cosmetics include skin, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutritional lotion, massage cream, nutritional cream moisture cream, hand cream, foundation, essence, nutritional essence, pack, arsenic, cleansing. These include, but are not limited to, foam, cleansing lotion, cleansing cream, body lotion, and body cleanser.
본 발명에 따른 약학적 조성물은 약학적으로 허용되는 담체와 함께 당업계에 공지된 방법으로 투여 경로에 따라 다양하게 제형화될 수 있다. 상기 담체로는 모든 종류의 용매, 분산매질, 수중유 또는 유중수 에멀젼, 수성 조성물, 리포좀, 마이크로비드 및 마이크로좀이 포함된다. The pharmaceutical composition according to the present invention can be formulated in various ways depending on the route of administration by methods known in the art along with a pharmaceutically acceptable carrier. The carrier includes all types of solvents, dispersion media, oil-in-water or water-in-oil emulsions, aqueous compositions, liposomes, microbeads and microsomes.
상기 본 발명에 따른 약학적 조성물은 약학적으로 유효한 양, 즉 피부 주름 개선, 피부 탄력 개선 및 피부 보습 개선 효과를 나타내기에 충분한 양으로 환자에게 투여될 수 있다. 예를 들어 일반적인 1일 투여량으로는 1 내지 10000mg 의 범위로 투여될 수 있으며, 바람직하게는, 10 내지 200mg의 범위로 투여될 수 있다. 본 발명의 약학적 조성물은 바람직한 투여량 범위 내에서 1회 또는 수회로 분할 투여할 수 있다. 또한 본 발명에 따른 약학적 조성물의 투여량은 투여 경로, 투여 대상, 연령, 성별 체중, 개인차 및 질병 상태에 따라 통상의 기술자가 적절하게 선택할 수 있다. The pharmaceutical composition according to the present invention can be administered to a patient in a pharmaceutically effective amount, that is, an amount sufficient to exhibit the effects of improving skin wrinkles, improving skin elasticity, and improving skin moisturization. For example, a general daily dose may be administered in the range of 1 to 10,000 mg, preferably in the range of 10 to 200 mg. The pharmaceutical composition of the present invention can be administered once or in divided doses within a preferred dosage range. Additionally, the dosage of the pharmaceutical composition according to the present invention can be appropriately selected by a person skilled in the art depending on the administration route, administration subject, age, gender, weight, individual differences, and disease state.
투여 경로로는 경구적 또는 비경구적으로 투여될 수 있다. 비경구적인 투여방법으로는 이에 한정되지는 않으나 정맥 내, 근육 내, 동맥 내, 골수 내, 경막 내, 심장 내, 경피, 피하, 복강 내, 비강 내, 장관, 국소, 설하, 직장, 또는 췌장 내 투여일 수 있으나, 이에 제한되지 않으며, 가장 바람직하게는 경구적으로 투여될 수 있다.The route of administration may be oral or parenteral. Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual, rectal, or pancreatic. It may be administered internally, but is not limited to this, and most preferably, it may be administered orally.
본 발명의 약학적 조성물을 경구 투여하는 경우, 적합한 경구 투여용 담체와 함께 당업계에 공지된 방법에 따라 분말, 과립, 정제, 환제, 당의정제, 캡슐제, 액제, 겔제, 시럽제, 현탁액, 웨이퍼 등의 형태로 제형화할 수 있다. 적합한 담체의 예로는 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨 및 말티톨 등을 포함하는 당류와 옥수수 전분, 밀 전분, 쌀 전분 및 감자 전분 등을 포함하는 전분류, 셀룰로즈, 메틸 셀룰로즈, 나트륨 카르복시메틸셀룰로오즈 및 하이드록시프로필메틸셀룰로즈 등을 포함하는 셀룰로즈류, 젤라틴, 폴리비닐피롤리돈 등과 같은 충전제가 포함될 수 있다. 또한, 경우에 따라 가교결합 폴리비닐피롤리돈, 한천, 알긴산 또는 나트륨 알기네이트 등을 붕해제로 첨가할 수 있다. 나아가, 상기 약학적 조성물은 항응집제, 윤활제, 습윤제, 향료, 유화제 및 방부제 등을 추가로 포함할 수 있다.When the pharmaceutical composition of the present invention is administered orally, powder, granules, tablets, pills, sugar-coated tablets, capsules, solutions, gels, syrups, suspensions, and wafers are prepared according to methods known in the art along with a suitable carrier for oral administration. It can be formulated in a form such as: Examples of suitable carriers include sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, starches including corn starch, wheat starch, rice starch and potato starch, cellulose, Fillers such as cellulose, including methyl cellulose, sodium carboxymethylcellulose, and hydroxypropylmethylcellulose, gelatin, polyvinylpyrrolidone, etc. may be included. Additionally, in some cases, cross-linked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may be added as a disintegrant. Furthermore, the pharmaceutical composition may further include anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, and preservatives.
또한, 비경구적으로 투여하는 경우, 본 발명의 약학적 조성물은 적합한 비경구용 담체와 함께 주사제, 경피투여제 및 비강 흡입제 등의 형태로 당 업계에 공지된 방법에 따라 제형화될 수 있다. In addition, when administered parenterally, the pharmaceutical composition of the present invention can be formulated with a suitable parenteral carrier in the form of injections, transdermal administration, nasal inhalation, etc. according to methods known in the art.
또한, 약학적 조성물은 활성 물질이 표적 세포로 이동할 수 있는 임의의 장치에 의해 투여될 수 있다. 바람직한 투여방식 및 제제는 정맥 주사제, 피하 주사제, 피내 주사제, 근육 주사제 또는 점적 주사제 등이다. 주사제는 생리식염액 또는 링겔액 등의 수성 용제, 식물유, 고급 지방산 에스테르 (예로, 올레인산에칠 등), 알코올류(예로, 에탄올, 벤질알코올, 프로필렌글리콜 또는 글리세린 등) 등의 비수성 용제 등을 이용하여 제조할 수 있고, 변질 방지를 위한 안정화제 (예로, 아스코르빈산, 아황산수소나트륨, 피로아황산나트륨, BHA, 토코페롤, EDTA 등), 유화제, pH 조절을 위한 완충제, 미생물 발육을 저지하기 위한 보존제 (예로, 질산페닐수은, 치메로살, 염화벤잘코늄, 페놀, 크레솔, 벤질알코올 등) 등의 약제학적 담체를 포함할 수 있다. Additionally, the pharmaceutical composition can be administered by any device that allows the active agent to move to target cells. Preferred administration methods and formulations include intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, or drip injection. Injections include aqueous solvents such as physiological saline solution or Ringer's solution, non-aqueous solvents such as vegetable oil, higher fatty acid esters (e.g., ethyl oleate, etc.), and alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, or glycerin, etc.). It can be manufactured using stabilizers to prevent deterioration (e.g., ascorbic acid, sodium bisulfite, sodium pyrosulfite, BHA, tocopherol, EDTA, etc.), emulsifiers, buffers for pH adjustment, and agents to prevent microbial growth. It may contain pharmaceutical carriers such as preservatives (e.g., phenylmercuric nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.).
상기 주사제의 경우에는 반드시 멸균되어야 하며 박테리아 및 진균과 같은 미생물의 오염으로부터 보호되어야 한다. 주사제의 경우 적합한 담체의 예로는 이에 한정되지는 않으나, 물, 에탄올, 폴리올(예를 들어, 글리세롤, 프로필렌 글리콜 및 액체 폴리에틸렌 글리콜 등), 이들의 혼합물 및/또는 식물유를 포함하는 용매 또는 분산매질일 수 있다. 보다 바람직하게는, 적합한 담체로는 행크스 용액, 링거 용액, 트리에탄올 아민이 함유된 PBS(phosphate buffered saline) 또는 주사용 멸균수, 10% 에탄올, 40% 프로필렌 글리콜 및 5% 덱스트로즈와 같은 등장 용액 등을 사용할 수 있다. 상기 주사제를 미생물 오염으로부터 보호하기 위해서는 파라벤, 클로로부탄올, 페놀, 소르빈산, 티메로살 등과 같은 다양한 항균제 및 항진균제를 추가로 포함할 수 있다. 또한, 상기 주사제는 대부분의 경우 당 또는 나트륨 클로라이드와 같은 등장화제를 추가로 포함할 수 있다. The above injections must be sterilized and protected from contamination by microorganisms such as bacteria and fungi. For injections, examples of suitable carriers include, but are not limited to, solvents or dispersion media including water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.), mixtures thereof, and/or vegetable oils. You can. More preferably, suitable carriers include Hanks' solution, Ringer's solution, phosphate buffered saline (PBS) containing triethanol amine, or isotonic solutions such as sterile water for injection, 10% ethanol, 40% propylene glycol, and 5% dextrose. etc. can be used. In order to protect the injection from microbial contamination, it may additionally contain various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. Additionally, in most cases, the injection may additionally contain an isotonic agent such as sugar or sodium chloride.
그 밖의 약학적으로 허용되는 담체로는 다음의 문헌에 기재되어 있는 것을 참고로 할 수 있다(Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).As for other pharmaceutically acceptable carriers, those described in the following literature may be referred to (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).
본 발명에 따른 약학적 조성물은 하나 이상의 완충제(예를 들어, 식염수 또는 PBS), 카보하이트레이트(예를 들어, 글루코스, 만노즈, 슈크로즈 또는 덱스트란), 항산화제, 정균제, 킬레이트화제(예를 들어, EDTA 또는 글루타치온), 아쥬반트(예를 들어, 알루미늄 하이드록사이드), 현탁제, 농후제 및/또는 보존제를 추가로 포함할 수 있다.The pharmaceutical composition according to the invention may contain one or more buffers (e.g. saline or PBS), carbohydrates (e.g. glucose, mannose, sucrose or dextran), antioxidants, bacteriostatic agents, chelating agents (e.g. For example, EDTA or glutathione), adjuvants (e.g. aluminum hydroxide), suspending agents, thickening agents and/or preservatives may be further included.
또한, 본 발명의 약학적 조성물은 포유동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 공지된 방법을 사용하여 제형화될 수 있다. Additionally, the pharmaceutical compositions of the present invention can be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
또한, 본 발명의 약학적 조성물은 단독으로 투여하거나, 피부 상태 개선에 효과가 있는 공지의 물질과 병용하여 투여할 수 있다. Additionally, the pharmaceutical composition of the present invention can be administered alone or in combination with known substances effective in improving skin condition.
유산균 발효 미배아 추출물을 포함하는 본 발명의 조성물은 자외선 자극에 의한 피부 표피 두께 증가 억제, 피부 콜라겐 감소 억제, 콜라겐 분해효소 발현 억제 및 각질세포에서 필라그린(filaggrin)의 발현 증가 효과를 나타내어 피부 주름 개선, 피부 탄력 개선 및 피부 보습 증진용 제제 개발에 매우 유용하게 활용될 수 있다. The composition of the present invention containing lactic acid bacteria-fermented rice germ extract inhibits the increase in skin epidermal thickness caused by ultraviolet ray stimulation, inhibits the decrease in skin collagen, inhibits the expression of collagen decomposition enzymes, and increases the expression of filaggrin in keratinocytes, thereby causing skin wrinkles. It can be very useful in developing agents for skin improvement, skin elasticity, and skin moisturization.
도 1은 각 동물군의 시험기간 동안 체중 변화를 나타낸 그래프이다.
도 2는 일반군(Normal), 자외선 조사군(UVB) 및 자외선 조사 후 시험물질 투여군(FRGE) 동물의 피부 주름을 4주, 8주 및 12주차에 replica로 관찰한 결과이다.
도 3은 replica 분석을 통한 각 동물군의 Total wrinkle area, Number of wrinkles, Total length, Mean length 및 Mean depth를 정량화하여 그래프로 나타낸 결과이다.
도 4는 각 동물군의 피부에서 붉은 정도(redness), 보습(hydration) 및 두께(caliper)를 4주, 8주 및 12주차에 관찰하여 정량화한 결과이다.
도 5는 각 동물군의 피부에서 피부 탄력성을 4주, 8주 및 12주차에 관찰하여 정량화한 결과이다.
도 6은 실험 종료 후 각 동물군의 피부 조직을 H&E 염색하여 현미경으로 관찰한 결과이다.
도 7은 실험 종료 후 각 동물군의 피부 조직을 Masson trichrome 염색하여 현미경으로 관찰한 결과이다.
도 8은 실험 종료 후 각 동물군의 피부 조직에서 MMP-3 mRNA의 발현 정도를 PCR로 관찰하고, 이를 정량화한 그래프이다.
도 9는 실험 종료 후 각 동물군의 피부 조직에서 filaggrin 단백질의 발현 정도를 웨스턴 블로팅으로 관찰하고, 이를 정량화한 그래프이다. Figure 1 is a graph showing the change in body weight of each animal group during the test period.
Figure 2 shows the results of observing the skin wrinkles of animals in the normal group (Normal), the ultraviolet irradiation group (UVB), and the test substance administration group after ultraviolet irradiation (FRGE) using replicas at 4, 8, and 12 weeks.
Figure 3 is a graph showing the results of quantifying the Total wrinkle area, Number of wrinkles, Total length, Mean length, and Mean depth of each animal group through replica analysis.
Figure 4 shows the results of quantification of redness, hydration, and thickness (caliper) in the skin of each animal group observed at 4, 8, and 12 weeks.
Figure 5 shows the results of quantification of skin elasticity observed in the skin of each animal group at 4, 8, and 12 weeks.
Figure 6 shows the results of H&E staining of skin tissue of each animal group and observation under a microscope after completion of the experiment.
Figure 7 shows the results of Masson trichrome staining of skin tissue of each animal group and observation under a microscope after completion of the experiment.
Figure 8 is a graph quantifying the expression level of MMP-3 mRNA observed by PCR in the skin tissue of each animal group after the end of the experiment.
Figure 9 is a graph observing and quantifying the expression level of filaggrin protein in skin tissue of each animal group by Western blotting after the end of the experiment.
이하, 본 발명을 하기 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명이 이들에 의해 제한되는 것은 아니다.Hereinafter, the present invention will be explained in detail by the following examples. However, the following examples are only for illustrating the present invention, and the present invention is not limited thereto.
실험방법Experiment method
1. 미배아 추출물 제조1. Preparation of rice embryo extract
㈜ 골든아이에서 구입한 미배아의 수분을 20%로 조정한 후 290℃ 과열수증기로 와류형 유동층 장치에서 20초 처리한 후 순간적으로 방출하면서 실온의 공기로 냉각하였다. 상기와 같이 과열수증기 처리하여 팽화한 미배아 25g과 10배수의 물을 500mL 삼각 플라스크에 가하고 상부를 알루미늄 포일로 밀봉하였다.The moisture of the unborn embryos purchased from GoldenEye Co., Ltd. was adjusted to 20%, then treated with superheated water vapor at 290°C for 20 seconds in a vortex-type fluidized bed device, and then instantly released and cooled with room temperature air. 25 g of unexpanded embryos treated with superheated water vapor as described above and 10 times the amount of water were added to a 500 mL Erlenmeyer flask, and the top was sealed with aluminum foil.
다른 미배아 시료는 실험실용 디스크형 분쇄기로 분쇄한 후 40메쉬 채를 통과하는 분획 25g을 10배수의 물에 현탁시킨 후 알카레이스(alcalase), 아밀레이스(amylase), 셀루크라스트(celluclast)를 각각 분쇄 미배아의 1% 되게 단독 또는 복합적으로 첨가하였다.Other unembryo samples were pulverized using a laboratory disk-type grinder, and then 25 g of the fraction passed through a 40-mesh sieve was suspended in 10 times the amount of water, and then alcalase, amylase, and celluclast were removed. Each was added singly or in combination at 1% of the ground embryo.
상기 과열 수증기 처리한 미배아 현탁액과 분쇄 후 가수분해 효소를 첨가한 미배아 현탁액 플라스크는 55℃ 수욕에서 교반하면서 18시간 추출한 후 13000rpm에서 15분간 원심분리하여 상등액을 얻고 상등액을 0.2㎛ 실린지 필터로 여과한 후 105℃ 건조법으로 상등액 중의 고형분량을 측정하였다. The superheated steam-treated US embryo suspension and the US embryo suspension flask to which hydrolytic enzymes were added after pulverization were extracted for 18 hours while stirring in a 55°C water bath, centrifuged at 13000 rpm for 15 minutes to obtain a supernatant, and the supernatant was filtered through a 0.2㎛ syringe filter. After filtration, the solid content in the supernatant was measured using a drying method at 105°C.
표 1에 나타낸 것과 같이 과열 수증기 처리로 순간적으로 배아를 수열팽화시킴으로서 추출 수율은 2배 이상 향상되었으며, 각종 효소가수분해 처리로 역시 추출 수율은 약 1.5배 내지 2배 증가하여 전처리라 유효함을 알 수 있다. As shown in Table 1, the extraction yield was improved by more than 2 times by instantaneously hydrothermally expanding the embryo through superheated steam treatment, and the extraction yield was also increased by about 1.5 to 2 times with various enzymatic hydrolysis treatments, showing that it is effective as a pretreatment. You can.
[표 1][Table 1]
2. 유산균 발효 미배아 추출물 시료 제조2. Preparation of lactic acid bacteria fermented rice embryo extract sample
발효생산시설을 이용하여 동물실험을 위한 유산균 발효 미배아 추출물 분말시료를 생산하였다. 우선 500L의 발효조에 미배아 10배수 추출물 배지 350L를 준비하고 여기에 실험실에서 전배양한 Lactobacillus. sakei B2-16균주 (기탁번호 KFCC11321) 배양액을 접종하여 30℃, 48시간 배양하였다. 발효 종료 후 발효액은 살균, 여과한 후 덱스트린을 첨가하고 대형 분무건조기에서 분무건조 하였으며, 알루미늄 적층 포장용기에 1kg 단위로 소포장 하였다.Using a fermentation production facility, powdered samples of lactic acid bacteria fermented rice embryo extract were produced for animal testing. First, prepare 350L of 10 embryo extract medium in a 500L fermenter and add Lactobacillus pre-cultured in the laboratory. sakei B2-16 strain (accession number KFCC11321) culture medium was inoculated and cultured at 30°C for 48 hours. After completion of fermentation, the fermented broth was sterilized and filtered, dextrin was added, spray dried in a large spray dryer, and small packages of 1 kg were placed in aluminum laminated packaging containers.
분말시료의 일반성분을 분석한 결과, 열량(Kcal/100g) 261.3, 회분(%) 28.5, 탄수화물(%) 45.9, 수분(%) 6.6, 조지방(%) 0.3, 나트륨(mg/100g) 3574.3 및 조단백질(%) 18.7으로 나타났으며, 자체분석 및 한국기능식품연구원에 분석 의뢰를 통하여 가바 함량은 15%(w/w)임을 확인하였다. As a result of analyzing the general components of the powder sample, calories (Kcal/100g) 261.3, ash (%) 28.5, carbohydrates (%) 45.9, moisture (%) 6.6, crude fat (%) 0.3, sodium (mg/100g) 3574.3, and The crude protein (%) was found to be 18.7, and the GABA content was confirmed to be 15% (w/w) through in-house analysis and by requesting analysis from the Korea Functional Food Research Institute.
3. 동물실험3. Animal testing
(1) 실험동물, 실험동물의 사육, 시험물질 및 주름유발(1) Experimental animals, breeding of experimental animals, test substances, and wrinkle-inducing
본 실험에서는 사용한 생쥐(mouse)는 일반적으로 피부 관련 시험에 널리 사용되고 있으며, 주름 유발이 용이하며 선천적으로 무모(hairless)인 HR-1 계통의 특정병원균 부재(SPF) 6주령의 무모생쥐(hairless mouse)를 중앙실험동물(주) (Seoul, Korea)에서 구입하여 7일간 순화기간을 두었으며, 순화기간 중 일반증상을 매일 관찰하여 건강한 동물만 실험에 사용하였다. 실험동물은 3개 군으로 분류하고 군별 각 10마리씩 배정하였다. 투여 개시 전일 각 실험동물의 체중을 측정하고 순위화한 체중을 이용하여 무작위법에 의해 군 분리를 하였다. 개체식별은 미부표시법 및 사육상자 별 개체식별카드 표시법을 이용하였다. The mouse used in this experiment is a 6-week-old hairless mouse that is widely used in skin-related tests and is specific pathogen-free (SPF) of the HR-1 strain, which easily causes wrinkles and is congenitally hairless. ) were purchased from Joongang Laboratory Animal Co., Ltd. (Seoul, Korea) and allowed to acclimate for 7 days. During the acclimatization period, general symptoms were observed daily and only healthy animals were used in the experiment. The experimental animals were divided into three groups and each group was assigned 10 animals. The weight of each experimental animal was measured the day before the start of administration, and the ranked weights were used to separate groups into groups using a random method. For individual identification, the tail marking method and individual identification card marking method for each breeding box were used.
사육기간 동안 사료와 물을 자유롭게 섭취하도록 하였으며, 동물실의 온도 23±3℃, 상대습도 55±15%, 암모니아 농도 5ppm 이하로 유지하였고, 명암 사이클은 형광등 조명으로 12시간 (08:00 점등 ~ 20:00 소등) 되도록 조절하였다. 사육실의 조도는 268Lux, 소음은 55.1dB, 암모니아 농도는 5ppm 이하로 유지하였다. 실험동물은 순화, 검역, 투여 및 관찰기간 중 스테인레스제 망 사육상자 (200W*260D*130Hmm)에 수용하였다.Feed and water were allowed to be consumed freely during the breeding period, and the temperature of the animal room was maintained at 23±3°C, relative humidity was 55±15%, and ammonia concentration was below 5ppm, and the light/dark cycle was 12 hours with fluorescent lighting (lights on at 08:00 ~ 20:00 (lights off). The illumination level of the breeding room was maintained at 268 Lux, the noise level at 55.1 dB, and the ammonia concentration at 5 ppm or less. Experimental animals were housed in stainless steel mesh breeding boxes (200W*260D*130Hmm) during the acclimatization, quarantine, administration, and observation periods.
실험군은 정상군(Normal), 자외선 조사군(UVB) 및 자외선 조사와 함께 유산균 발효 미배아 추출물 섭취군(FRGE)으로 나누었다. 시험물질은 각 군별 사료에 혼합하여 고형분을 경구 투여하였다. 유산균 발효 미배아 추출물 섭취군(FRGE)은 상기 실험방법 2의 제조방법으로 제조한 유산균 발효 미배아 추출물 분말시료를 100mg(체중/day/mouse) 되게 첨가한 고형분 식이를 투여하였다. The experimental group was divided into a normal group (Normal), an ultraviolet irradiation group (UVB), and a group that consumed lactic acid bacteria fermented rice germ extract (FRGE) along with ultraviolet irradiation. The test substances were mixed into the feed for each group and administered orally as solid content. The lactic acid bacteria fermented rice germ extract consumption group (FRGE) was administered a solid diet to which 100 mg (body weight/day/mouse) of the lactic acid bacteria fermented rice embryo extract powder sample prepared by the method of Experiment 2 above was added.
실험사육기간 동안 무모생쥐의 등 부분에 Philips TL20W/12를 사용하여 자외선(UV)을 주 3회 조사하였다. 자외선 조사량은 Walkmann UV meter를 사용하여 조사 시 마다 측정하였다. 조사량은 1주째 1MED (80mJ/cm2)로 시작하여 1주마다 1MED 씩 늘렸으며 4주 이후는 4MED를 조사하였으며, 피부 상태 및 적절한 주름이 형성되도록 조사량을 조절하였다. 총 80MED의 자외선을 조사하였다.During the experimental breeding period, the backs of hairless mice were irradiated with ultraviolet rays (UV) three times a week using Philips TL20W/12. The amount of ultraviolet irradiation was measured at each irradiation using a Walkmann UV meter. The irradiation dose started at 1 MED (80 mJ/cm2) in the first week and increased by 1 MED every week. After 4 weeks, 4 MED was administered, and the irradiation dose was adjusted to ensure skin condition and appropriate wrinkle formation. A total of 80 MED of ultraviolet rays were irradiated.
(2) 시험항목 (2) Test items
① 일반증상관찰① Observation of general symptoms
모든 동물에 대하여 매일 1회 일반증상관찰을 실시하였으며, UV조사 당일에는 조사 직후 및 그 이후 6시간까지 매시간 마다 관찰하였다, 일반증상관찰은 시험이 종료되는 시점까지 계속 실시하였다.All animals were observed for general symptoms once a day. On the day of UV irradiation, observations were made immediately after irradiation and every hour for 6 hours thereafter. General symptom observation continued until the end of the test.
②체중 측정②Weight measurement
체중은 모든 동물에 대하여 주 1회(월요일) 일정한 시간 (오후03:00)에 측정하였다.Body weight was measured once a week (Monday) at a certain time (03:00 PM) for all animals.
③ 실체 현미경 촬영③ Stereoscopic microscope photography
등 피부 부위의 실체현미경 사진은 4, 8, 12주에 SMZ1500(Nikon Japan)를 이용하여 촬영을 하였다.Stereomicroscopic images of the back skin area were taken using SMZ1500 (Nikon Japan) at 4, 8, and 12 weeks.
④ 모사판 제작④ Production of copy version
무모생쥐의 등 부분에 구멍이 있는 디스크를 부착하고 실리콘 고무 (Silflo: Flexico Developments Ltd, England) 시약을 혼합하여 디스크면에 얇게 펴 바르고 완전히 건조시킨 다음 조심스럽게 떼어내어 모사판 (replica)을 제작하였다. 모사판은 4, 8, 12주차에 제작하였으며, 피부주름 측정장치를 이용하여 주름의 면적, 수, 총길이, 평균길이 및 평균 깊이를 분석하였다. A disk with a hole was attached to the back of a hairless mouse, a silicone rubber (Silflo: Flexico Developments Ltd, England) reagent was mixed, spread thinly on the surface of the disk, dried completely, and then carefully removed to create a replica. . Simulation plates were produced at weeks 4, 8, and 12, and the area, number, total length, average length, and average depth of wrinkles were analyzed using a skin wrinkle measuring device.
⑤ 수분 함량, 탄력도, 홍반 측정⑤ Measurement of moisture content, elasticity, and erythema
피부 수분함량 및 탄력은 replica 제작 부위와 동일한 부위에서 측정하였다. 피부의 수분함량은 Corneometer (Courage and Khazaka, Germany)로 4, 8, 12주에 측정하였다. Skin moisture content and elasticity were measured in the same area as the replica production area. Skin moisture content was measured at 4, 8, and 12 weeks using a Corneometer (Courage and Khazaka, Germany).
피부탄력은 Cutometer(Courage and Khazaka, Germany)로 4, 8, 12주에 측정하였다. 음압 50 mbar, 흡입 1초 후 1초 측정을 3회 반복하여 R0~9, F0~1을 분석하였다. Skin elasticity was measured at 4, 8, and 12 weeks using Cutometer (Courage and Khazaka, Germany). R0~9 and F0~1 were analyzed by repeating 1 second measurement at a sound pressure of 50 mbar and 1 second after inhalation three times.
자외선 조사에 의해 발생되는 홍반(erythema)은 spectrophotometer (KONICA MINOLTA, Tokyo, Japan)로 측정했다.Erythema caused by ultraviolet irradiation was measured with a spectrophotometer (KONICA MINOLTA, Tokyo, Japan).
⑥ 조직 검사⑥ Biopsy
시험 종료 시에 등 부위의 피부를 적출하여 포르말린으로 고정했다. 단계별로 alcohol과 xylene으로 탈수처리한 후 파라핀으로 포매한 후, 마이크로톰을 이용하여 5㎛ 이하의 절편을 만들어 다시 alcohol과 xylene으로 파라핀을 제거했다. At the end of the test, the skin on the back was removed and fixed in formalin. After step-by-step dehydration with alcohol and xylene, embedding in paraffin, sections of less than 5㎛ were made using a microtome, and the paraffin was removed again with alcohol and xylene.
Hematoxylin & Eosin (H&E) 염색하여 표피의 두께를 NIS-Elements(Nikon, Japan)으로 측정했다. 또한 Masson trichrome 염색을 실시하여 콜라겐 생성을 측정했다. Hematoxylin & Eosin (H&E) staining was performed and epidermal thickness was measured using NIS-Elements (Nikon, Japan). Additionally, Masson trichrome staining was performed to measure collagen production.
⑦ MMP-3 및 filaggrin analysis⑦ MMP-3 and filaggrin analysis
피부 조직을 추출하여 RNA를 추출하고 cDNA로 합성하여 MMP-3의 발현량을 RT-PCR 방법을 통해 분석했다. 또한, 피부 조직에서 단백질을 추출하여 filaggrin 발현량을 western blotting 방법을 통해 분석했다. Skin tissue was extracted, RNA was extracted, synthesized into cDNA, and the expression level of MMP-3 was analyzed using RT-PCR. In addition, proteins were extracted from skin tissue and filaggrin expression levels were analyzed using western blotting.
실험결과Experiment result
1. 일반증상 및 체중의 변화 (도 1)1. General symptoms and changes in weight (Figure 1)
시험 기간 중 모든 시험계에서 시험물질 경구투여로 인한 특이한 임상증상은 관찰되지 않았다. 체중 역시 모두 정상적인 증가를 나타내어 통계적으로 유의한 차이가 없었다 (도 1). No unusual clinical symptoms due to oral administration of test substances were observed in any test system during the test period. Body weight also showed a normal increase, with no statistically significant difference (Figure 1).
2. 무모 마우스의 피부주름 생성 변화 (도 2, 도 3))2. Changes in skin wrinkle formation in hairless mice (Figures 2 and 3))
유산균 발효 미배아 추출물의 섭취가 피부주름의 형성 정도에 미치는 영향을 평가하기 위하여 육안과 실험동물의 등피부 부위 모사판(replica)을 이용하여 4, 8, 12주차에 주름의 면적, 수, 총 길이, 평균 길이 및 평균 깊이를 측정하고 통계처리 하였다.To evaluate the effect of ingestion of lactic acid bacteria-fermented rice germ extract on the degree of skin wrinkle formation, the area, number, and total number of wrinkles were measured at 4, 8, and 12 weeks using the naked eye and replicas of the back skin of experimental animals. Length, average length, and average depth were measured and statistically processed.
UV 조사기간 12주 동안 육안으로 관찰했을 때 자외선에 반복적으로 노출된 UVB 대조군은 조사받지 않은 정상군 (Normal)에 비해 다수의 굵고 깊이 패인 주름과 함께 잔주름 형성이 비정상적으로 증가한 것이 관찰되었다(도 2). 유산균 발효 미배아 추출물 섭취군(FRGE)은 UVB군에 비하여 주름의 굵기와 깊이가 현저히 개선된 것을 확인하였다(도 2). When observed with the naked eye during the 12-week UV irradiation period, the UVB control group repeatedly exposed to ultraviolet rays was observed to have numerous thick and deep wrinkles and an abnormal increase in the formation of fine wrinkles compared to the non-irradiated normal group (Figure 2) ). It was confirmed that the thickness and depth of wrinkles in the lactic acid bacteria fermented rice germ extract consumption group (FRGE) were significantly improved compared to the UVB group (Figure 2).
모사판 분석을 통해 주름의 총 면적, 총 수, 총 길이, 평균 길이 및 평균 깊이를 객관적으로 평가한 결과 FRGE 섭취군은 UVB군과 비교하여 주름 생성 및 주름에 관련된 지표들이 전체적으로 유의적 (p<0.05)으로 감소하였다(도 3).As a result of objectively evaluating the total area, total number, total length, average length, and average depth of wrinkles through simulation plate analysis, the FRGE intake group showed overall significant signs related to wrinkle formation and wrinkles compared to the UVB group (p< 0.05) (Figure 3).
3. 홍반도, 피부수화 및 피부두께 (도 4)3. Erythema, skin hydration and skin thickness (Figure 4)
실험 기간 4, 8, 12주차에 FRGE 섭취군은 UVB군 보다 홍반도 및 피부두께가 유의적으로 감소한 것을 확인하였다(p<0.05). In the 4th, 8th, and 12th weeks of the experiment period, the FRGE intake group showed a significant decrease in erythema and skin thickness compared to the UVB group (p<0.05).
그리고 skin hydration 함유량은 FRGE 섭취군이 UVB군 보다 유의적으로 증가하였다(p<0.05). And the skin hydration content in the FRGE intake group significantly increased compared to the UVB group (p<0.05).
4. 피부 탄력성 측정(도 5)4. Measurement of skin elasticity (Figure 5)
시험물질 경구투여 4, 8, 12주차에 Cutometer을 이용하여 피부의 탄력성을 측정하였다. 피부는 점탄성체로서 피부의 변형은 탄성변형과 점성변형이 복합적으로 일어난다. R2(=Ua/Uf, 총점탄성)는 흡입 10초에서 프로브에 최대로 끌어 올려 진 피부(Uf)가 얼마나 윈래 상태로 돌아갈 수(Ua) 있는지를 나타내는 값으로 1(100%)에 가까울수록 점탄성이 크다는 것을 의미하며, R5(=Ur/Ue, 순탄성)는 프로브에 흡입된 직후에 인상된 피부 높이(Ue)와 흡입을 개방하여 인상된 피부를 뗀 직후에 되돌아간 피부 높이(회복된 탄성부분) (Ur)의 비율로 1(100%)에 가까울수록 더욱 탄성적 피부란 의미이다, R7(=Ur/Uf, 회복율)은 10초에서 최대로 끌어 오른 피부 높이에서 탄성부분이 얼마나 비중을 차지하는 지를 나타내는 값이다, Skin elasticity was measured using a Cutometer at 4, 8, and 12 weeks after oral administration of the test substance. Skin is a viscoelastic material, and its deformation occurs through a combination of elastic deformation and viscous deformation. R2 (=Ua/Uf, total viscoelasticity) is a value that indicates how much the skin (Uf) that is maximally pulled up by the probe can return to its original state (Ua) at 10 seconds of suction. The closer it is to 1 (100%), the more viscoelastic it is. This means that R5 (=Ur/Ue, net elasticity) is the ratio of the skin height (Ue) lifted immediately after being suctioned by the probe and the skin height (recovered elasticity) returned immediately after the skin was lifted by opening the suction. Part) As a ratio of (Ur), the closer it is to 1 (100%), the more elastic the skin is. R7 (=Ur/Uf, recovery rate) is the proportion of the elastic part at the maximum skin height in 10 seconds. It is a value that indicates how much it occupies.
피부 탄력성 측정 결과 FRGE 섭취군의 8주와 12주 후 R2, R5 및 R7 값이 모두 UVB군에 비하여 유의하게 높은 값을 나타내어(p<0.05) 자외선 조사에 의해 감소된 피부탄력성이 회복된 것으로 나타났다. As a result of measuring skin elasticity, after 8 and 12 weeks in the FRGE intake group, the R2, R5, and R7 values were all significantly higher than those in the UVB group (p<0.05), showing that the skin elasticity decreased by ultraviolet irradiation was recovered. .
5. 조직학적 평가 (도 6, 도 7)5. Histological evaluation (Figure 6, Figure 7)
시험물질 경구투여 마지막 날 조직병리학적 변화를 확인하기 위하여 헤마톡실린 및 에오신 (Hematoxylin and Ecosin, H&E)으로 염색한 뒤 조직분석을 하였다. 조직병리학적 결과, UVB군은 자외선 조사를 받지 않은 Normal군에 비해 피부 표피층 두께가 현저히 비후해진 것이 관찰되었다. 자외선 조사 등에 의하여 광노화가 진행되면 피부 진피층을 보호하기 위하여 각질층 형성이 증가하여 피부가 두꺼워지므로 표피층 두께가 두꺼워졌다는 것은 그만큼 광노화에 의한 피부손상이 크다는 것을 의미한다. 한편 유산균 발효 미배아 추출물을 섭취한 FRGE군은 표피 두께가 현저히 감소하여 Normal군과 거의 비슷하여 유산균 발효 미배아 추출물 섭취로 광노화에 의한 조직변화가 회복되었음을 알 수 있다 (도 6). To confirm histopathological changes on the last day of oral administration of the test substance, tissue analysis was performed after staining with hematoxylin and eosin (H&E). As a result of histopathology, it was observed that the thickness of the epidermal layer of the skin in the UVB group was significantly thickened compared to the normal group that did not receive ultraviolet irradiation. When photoaging progresses due to ultraviolet irradiation, etc., the formation of the stratum corneum increases to protect the dermal layer of the skin, making the skin thicker. Therefore, a thicker epidermal layer means that the skin damage caused by photoaging is greater. Meanwhile, the FRGE group that consumed the lactic acid bacteria-fermented rice germ extract had a significant decrease in epidermal thickness, which was almost similar to the Normal group, indicating that the tissue changes caused by photoaging were restored by the intake of the lactic acid bacteria-fermented rice embryo extract (Figure 6).
진피층에서 교원질의 확인을 위하여 마손 삼색염색(Masson Trichrome staining)을 한 결과 UVB군은 Normal군에 비해 진피층 상부에서 염색상 손실이 관찰되어 콜라겐이 적어진 것을 확인하였고 FRGE 섭취군에서는 진피층 손상이 관찰되지 않아 유산균 발효 미배아 추출물 섭취에 의해 콜라겐이 회복된 것을 확인하였다 (도 7),As a result of Masson Trichrome staining to confirm collagen in the dermal layer, it was confirmed that the UVB group had less collagen as staining loss was observed in the upper dermal layer compared to the Normal group, and no dermal layer damage was observed in the FRGE intake group. It was confirmed that collagen was restored by consuming lactic acid bacteria fermented rice germ extract (Figure 7).
6. RT-PCR방법을 이용한 MMP-3 mRNA 발현량 비교 (도 8)6. Comparison of MMP-3 mRNA expression level using RT-PCR method (Figure 8)
UVB 조사에 의해 활성화되어 type IV 등의 콜라겐을 분해하는 MMP-3 효소 유전자의 mRNA 발현량을 RT-PCR을 이용하여 피부조직에서 측정한 결과는 도 8와 같다. UVB군은 Normal군에 비해 MMP-3 발현량이 유의적으로 증가하였다. FRGE 섭취군은 UVB군에 비해 MMP-3 발현량이 유의적으로 낮게 나옴으로써(p<0.05) 유산균 발효 미배아 추출물 섭취는 세포 외 기질단백질의 분해를 억제시키는 효과가 있음을 나타내었다.The results of measuring the mRNA expression level of the MMP-3 enzyme gene, which is activated by UVB irradiation and decomposes collagen such as type IV, in skin tissue using RT-PCR are shown in Figure 8. The UVB group showed a significant increase in MMP-3 expression compared to the Normal group. The FRGE intake group showed significantly lower MMP-3 expression levels than the UVB group (p<0.05), indicating that intake of lactic acid bacteria fermented rice embryo extract had an effect of inhibiting the decomposition of extracellular matrix proteins.
7. Western blot 방법을 이용한 filaggrin 측정 (도 9)7. Measurement of filaggrin using Western blot method (Figure 9)
피부장벽을 이루는 keratinocyte에 포함된 보습성분 단백질인 filaggrin의 발현량을 Western blot을 이용하여 측정하였다. UVB군은 Normal군에 비하여 filaggrin 발현이 감소하였으며, FRGE 섭취군은 UVB군에 비해 filaggrin 발현이 유의적으로 증가하였다(p<0.05). The expression level of filaggrin, a moisturizing protein contained in keratinocytes forming the skin barrier, was measured using Western blot. In the UVB group, filaggrin expression decreased compared to the Normal group, and in the FRGE intake group, filaggrin expression significantly increased compared to the UVB group (p<0.05).
이상의 실험 결과 유산균 발효 미배아 추출물을 경구반복투여 했을 때 자외선에 의해 유발된 피부에 주름생성 억제, 보습 및 탄력 회복 효과를 지닌 것을 유의적으로 확인할 수 있었다.As a result of the above experiment, it was significantly confirmed that repeated oral administration of lactic acid bacteria fermented rice germ extract had the effect of suppressing wrinkle formation, moisturizing, and restoring elasticity to the skin caused by ultraviolet rays.
유산균 발효 미배아 추출물을 포함하는 본 발명의 조성물은 자외선 자극에 의한 피부 표피 두께 증가 억제, 피부 콜라겐 감소 억제, 콜라겐 분해효소 발현 억제 및 각질세포에서 필라그린(filaggrin)의 발현 증가 효과를 나타내어 피부 주름 개선, 피부 탄력 개선 및 피부 보습 증진용 제제 개발에 매우 유용하게 활용될 수 있어 산업상 이용가능성이 매우 높다. The composition of the present invention containing lactic acid bacteria-fermented rice germ extract inhibits the increase in skin epidermal thickness caused by ultraviolet ray stimulation, inhibits the decrease in skin collagen, inhibits the expression of collagen decomposition enzymes, and increases the expression of filaggrin in keratinocytes, thereby causing skin wrinkles. It can be very useful in developing agents for skin improvement, skin elasticity, and skin moisturization, so its industrial applicability is very high.
Claims (14)
A food composition for improving skin elasticity or wrinkles containing lactic acid bacteria fermented rice germ extract as an active ingredient.
A food composition for improving skin moisturization containing lactic acid bacteria fermented rice germ extract as an active ingredient.
The method of claim 1 or 2, wherein the lactic acid bacteria fermented rice embryo extract is powder or granular containing 5 to 90% (w/w) of GABA (γ-aminobutyric acid, GABA), or 20 to 80% (w) of GABA. /w) A food composition characterized in that it is one selected from the group consisting of a concentrate containing GABA and crystals containing 90% to less than 100% (w/w) GABA.
The food composition according to claim 1 or 2, wherein the lactic acid bacteria fermented rice embryo extract is obtained by fermenting the rice embryo extract with Lactobacillus sakei B2-16 (accession number KFCC11321).
The food composition according to claim 4, wherein the ungerm extract is extracted with one or more solvents selected from the group consisting of water, alcohols having 1 to 8 carbon atoms, and mixed solvents thereof.
The food composition according to claim 1 or 2, wherein the rice embryo extract is an extract of a rice embryo hydrothermally expanded with superheated steam, a rice embryo hydrolyzed by enzymes, or a combination thereof.
The food composition according to claim 6, wherein the enzyme is at least one selected from the group consisting of alcalase, amylase, and celluclast.
The method of claim 1 or 2, wherein the rice embryo extract is a rice embryo hydrothermally expanded with superheated steam, an enzymatically hydrolyzed rice embryo, or a combination thereof, Lactobacillus sakei B2-16 (accession number KFCC11321). ) A food composition characterized in that it is extracted after fermentation.
The method of claim 1 or 2, wherein the lactic acid bacteria fermented rice germ extract inhibits the increase in skin epidermal thickness caused by ultraviolet ray stimulation, inhibits the decrease in skin collagen, inhibits the expression of collagen degrading enzymes, and increases the expression of filaggrin in keratinocytes. A food composition characterized in that it exhibits at least one effect selected from the group consisting of.
The food composition according to claim 1 or 2, wherein the food composition is a health functional food.
A pharmaceutical composition for improving skin elasticity or wrinkles containing lactic acid bacteria fermented rice germ extract as an active ingredient.
A pharmaceutical composition for improving skin moisturization containing lactic acid bacteria fermented rice germ extract as an active ingredient.
A cosmetic composition for improving skin elasticity or wrinkles containing lactic acid bacteria fermented rice germ extract as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220078104A KR20240001759A (en) | 2022-06-27 | 2022-06-27 | Composition for improving skin conditions comprising lactic acid bacteria fermentate of rice germ extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220078104A KR20240001759A (en) | 2022-06-27 | 2022-06-27 | Composition for improving skin conditions comprising lactic acid bacteria fermentate of rice germ extract |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20240001759A true KR20240001759A (en) | 2024-01-04 |
Family
ID=89542626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220078104A KR20240001759A (en) | 2022-06-27 | 2022-06-27 | Composition for improving skin conditions comprising lactic acid bacteria fermentate of rice germ extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20240001759A (en) |
-
2022
- 2022-06-27 KR KR1020220078104A patent/KR20240001759A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6670166B2 (en) | Cosmetics | |
JP5791009B2 (en) | Lactic acid bacteria and food or drink using them | |
KR101791516B1 (en) | Functional cosmetic composition comprising complex ferment consisting of soybean and barley | |
JP2008201773A (en) | External preparation for skin | |
JP6969067B2 (en) | Anti-inflammatory, anti-aging and whitening agents | |
KR102121944B1 (en) | Cosmetic composition comprising extract of bud of Nypa fruiticans | |
JP2014508139A (en) | New uses of flavone compounds | |
KR101980361B1 (en) | Collagen hydrolysate having high concentration of collagen tripeptide and uses thereof | |
CN113694115A (en) | Application of Fuzhuan tea extract in preparation of skin conditioning product | |
JP2017114814A (en) | Cosmetics | |
KR101336804B1 (en) | Fermented ear shell using mushroom, manufacturing method thereof and cosmetic composition comprising the same | |
KR100974627B1 (en) | Fermented spirulina extract and method for preparing the same | |
JP2009029710A (en) | ANTIOXIDANT, ANTI-AGEING AGENT, ANTI-INFLAMMATORY AGENT, HAIR-GROWING AGENT, ANTI-OBESITY AGENT, AND ENDOTHELIN-1mRNA EXPRESSION INCREASE-INHIBITING AGENT, AND COSMETIC AND FOOD AND DRINK FOR BEAUTY | |
JP6482930B2 (en) | Skin cosmetics and foods and drinks | |
KR100843745B1 (en) | Fermented spirulina extract and method for preparing the same | |
JP2024015051A (en) | PROFILAGGRIN mRNA EXPRESSION PROMOTER, SERINE PALMITOYL TRANSFERASE mRNA EXPRESSION PROMOTER, AND HYALURONAN SYNTHASE 3 mRNA EXPRESSION PROMOTER | |
KR101437997B1 (en) | Fermented caviar extract and its cosmetic usage | |
KR101996732B1 (en) | Cosmetic composition comprising concentrate of Omegiju fermented using magma seawater for improving wrinkles, elasticity or moisturizing the skin | |
US20100317736A1 (en) | Composition of the skin external application or the food for accelerating proline recycling by containing theanine | |
JP6666650B2 (en) | Skin cosmetics, hair cosmetics and foods and drinks | |
KR20240001759A (en) | Composition for improving skin conditions comprising lactic acid bacteria fermentate of rice germ extract | |
KR20120117116A (en) | Cosmetic compositions for preventing skin cell death comprising extracts of fermented red ginseng | |
JP7082827B2 (en) | Cosmetics | |
WO2020203933A1 (en) | Antiaging agent, antioxidant, antiinflammatory agent and whitening agent, and cosmetic | |
KR20160014321A (en) | Cosmetic composition having anti-wrinkle effect containing the Fermented extract of Walnuts, Chestnuts |